Morcellator Hysterectomy and Myomectomy
Many laparoscopic hysterectomies and myomectomies are performed using a power morcellator. This is largely because the surgery requires a minimally invasive two centimeter incision to extract either the uterus or uterine fibroids.
It has been estimated that around 500,000 women undergo hysterectomies on an annual basis. Of this total, roughly 11 percent of hysterectomies are performed using a power morcellator, meaning roughly 50,000 women undergo laparoscopic morcellation hysterectomies annually. Many women make the choice to undergo a power morcellator hysterectomy or myomectomy, because both procedures offer shorter post-op recovery times.
This means that thousands of women across the country undergo this procedure without being told that a power morcellator hysterectomy or myomectomy subjects them to a dangerous side effect: spreading uterine sarcoma cancer.
Power Morcellators Spread Cancer
According to the FDA, a power morcellator may spread cancer in women that have undergone a laparoscopic hysterectomy (surgery to remove uterus) or myomectomy (surgery to remove uterine fibroid tissue).
If laparoscopic power morcellation is performed in women with unsuspected uterine sarcoma, there is a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis, significantly worsening the patient’s likelihood of long-term survival. For this reason, and because there is no reliable method for predicting whether a woman with fibroids may have a uterine sarcoma, the FDA discourages the use of laparoscopic power morcellation during hysterectomy or myomectomy for uterine fibroids.
Source: Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication issued on April 17, 2014
What is a Power Morcellator?
A laparoscopic power morcellator is a medical instrument used in various types of laparoscopic (minimally invasive) surgeries, such as hysterectomy or myomectomy. The device itself, which is also referred to as an electric morcellator, is electronically-powered and employs a rapidly-spinning blade to break up large tissue masses into small fragments (the word ‘morcellation’ means the division of tissue into smaller fragments). These small pieces of tissue are then vacuumed out of the body.
What Does a Power Morcellator Do?
The use of a power morcellator allows gynecologists and surgeons to make minimally invasive incisions (less than 2 centimeters) in order to remove fibroids and other tissue. By using smaller entry points, significant cuts through the stomach muscles are avoided. These small incisions allow patients to heal quicker with less post-op pain and fewer complications with the wound.
What is Vaginal Morcellation?
People occasionally confuse power morcellation with vaginal morcellation. Power morcellation uses tiny incisions to remove tissue through the abdomen. A power morcellator is not often used in vaginal morcellation. Rather than using a power morcellator device, a surgeon dissects the tissue using a scalpel, and then removes it through the vagina.
In vaginal morcellation, surgeons carefully put the uterus or uterine fibroid tissue into a protective bag before cutting, preventing any cancerous tissue from spreading. This is in contrast to the use of a power morcellator, which can allow cancer cells to spread in the abdominal cavity.
What Are Uterine Fibroids?
Also known as leiomyomas, uterine fibroids are noncancerous growths developing from muscular tissue of the uterus. At some point, most women will develop uterine fibroids, though most cases do not produce any symptoms. However, fibroids occasionally do cause symptoms like heavy or prolonged menstrual bleeding, pelvic pain or pressure, or frequent urination. If these symptoms are revealed, medical or surgical therapy is typically suggested.
Uterine cancer is one of the most common cancers among women, falling behind breast cancer, lung cancer and colorectal cancer. According to the FDA, roughly 95 percent of uterine cancers occur in the endometrium, which is the inner lining of the uterus. Endometrial cancer is treatable, with five-year survival rates reaching more than 80 percent, according to recent data. Tumors that occur on the outer muscular lining—sarcomas—are far more aggressive.
While medical opinions vary on the causes of uterine cancer, a variety of risk factors have been shown to increase the chances of developing the disease. High risk factors for uterine cancer include:
- High levels of estrogen
- Family history of uterine cancer
- Over the age of 40
Certain drugs have also been shown to increase one’s risk of developing uterine cancer. These include drugs used in hormone replacement therapy and others used to treat breast cancer.
Uterine Cancer Symptoms
Before undergoing a power morcellation procedure, a woman may have undetected Stage 1 uterine cancer. This is at the very heart of why power morcellators are so dangerous. The morcellator shreds fibroids, which can spread undetected cancer cells and potentially make it possible for cancer to grow in other areas of the body. In effect, the procedure seeds the cancer, causing it to metastasize and grow from Stage I to Stage IV in a relatively short amount of time.
When a tumor has spread to the bladder, lymph nodes, rectum or distant organs, it is considered Stage IV. Once a tumor reaches Stage IV, treatment options are narrowed. If you have undergone a power morcellator procedure and are experiencing any of the following symptoms, you need to speak with your physician as soon as possible:
- Abnormal vaginal bleeding or discharge
- Pain with urination or sex
- Pelvic or abdominal pain
- Pelvic or abdominal swelling
- Abnormal weight loss
- Nausea or vomiting
Leiomyosarcoma (LMS) is a very rare and aggressive form of cancer. Leiomyosarcomas are malignant tumors that develop from smooth muscle tissue cells that make up the involuntary muscles in your body. These involuntary muscles—ones that we do not move consciously with our brain—are found in the uterus, intestines, lungs, liver, stomach, the walls of all blood vessels, and our skin.
For the most part, uterine leiomyosarcoma (ULMS) occurs in women between the ages of 40 and 60 and accounts for roughly one percent of all uterine cancer diagnoses. Leiomyosarcoma tumors can be highly metastatic (easily spread to other parts of the body from where the cancer began). Roughly 70 percent of patients that undergo treatment for leiomyosarcoma see a recurrence of the disease within eight to 16 months. This is true even for women with Stage I or State II cases of leiomyosarcoma, where the disease has not spread outside of the uterus.
In roughly 80 percent of the women who see a recurrence, the disease metastasizes to other parts of the body (referred to as metastatic leiomyosarcoma, classified as Stage III or Stage IV), most commonly to the ovaries, the lungs or the liver. The five-year survival rate for women with non-metastatic leiomyosarcoma is roughly 50 percent. For those with metastatic leiomyosarcoma, the five-year survival rate is estimated to drop to between 4 and 16 percent.
Alternatives to Power Morcellator Hysterectomy and Myomectomy
According to the FDA, evidence has shown that, when feasible, vaginal hysterectomies produce comparable or better results and have fewer complications than laparoscopic or abdominal hysterectomy. Other treatment options for women with symptomatic uterine fibroids include:
- Traditional surgical hysterectomy and myomectomy (performed vaginally)
- Laparotomy using a smaller incision (minilaparotomy)
- Laparoscopic hysterectomy and myomectomy without morcellation
- Deliberate blocking of uterine artery (catheter-based uterine artery embolization)
- High-intensity focused ultrasound
- Drug therapy
Types of Power Morcellators
Surgeons use two different power morcellation techniques: laparoscopic and hysteroscopic. Laparoscopic procedures carry the risk of developing uterine sarcoma cancer.
Most power morcellators currently in use are laparoscopic. Laparoscopic power morcellators make a small incision in the abdomen and tissue is shredded and removed. According to the FDA, laparoscopic power morcellator procedures can spread cancerous tissue to the pelvic cavity and the abdomen.
Hysteroscopic morcellators have tissue traps built into them, something that laparoscopic power morcellators lack. When surgeons shred tissue using this technique, it is collected in a pouch to be tested. Hysteroscopic devices, which are mechanical versus electric, have not been linked to an increased risk of uterine sarcoma cancer.
Laparoscopic Power Morcellator Manufacturers and Devices
Ethicon / Johnson & Johnson
- Gynecare Morcellex Tissue Morcellator
- Morcellex Sigma Tissue Morcellator System
- Gynecare X-Tract Tissue Morcellator
- Diva by FemRx
- VersaCut+Tissue Morcellator
- PKS PlasmaSORD
- VarioCarve Morcellator
Karl Storz GmbH
- KSE Steiner Electromechanic Morcellator
Richard Wolf GmbH
Cook Urological Inc.
Smith & Nephew
- TRUCLEAR Morcellation System
Other Power Morcellator Procedures
A power morcellator can also be used in certain kidney, liver and spleen procedures, allowing cancer to spread to other parts of the body. Cases of infection, abscess, and pelvic pain stemming from laparoscopic renal surgery and laparoscopic spleen surgery have been reported in the literature. Power morcellators have also been shown to cause injuries to surrounding organs within the abdominal cavity in men and women.
Report Adverse Events to the FDA
Prompt reporting of adverse events can help the FDA identify and better understand the risks associated with medical devices. If you suspect that a morcellator and/or specimen bag has malfunctioned or contributed to a serious injury or adverse outcome, the FDA encourages you to file a voluntary report through MedWatch, the FDA Safety Information and Adverse Event Reporting program.
Contact a Morcellator lawyer at Baum, Hedlund, Aristei & Goldman
Our team of experienced product liability medical device attorneys know what it takes to go the distance against major pharmaceutical and medical device manufacturers—we have been doing it for decades and our track record speaks for itself.
Baum, Hedlund, Aristei & Goldman is a preeminent plaintiffs firm that has successfully represented thousands of clients in defective medical device and pharmaceutical product liability cases. We have been on the prevailing side of some of our country’s most highly-publicized cases, recovering over $1.6 billion for our past clients in all areas of practice.*
Many of our product liability attorneys have earned Martindale-Hubbell’s highest AV® Preeminent™ Peer Review Rating, and Baum Hedlund is also listed in Martindale-Hubbell’s Bar Register Preeminent Lawyers, The Best Lawyers in America® for 2014-15, Top Ranked Law Firms™ for 2014-15, and five of the firm’s attorneys are listed in the Nation’s Top One Percent, National Association of Distinguished Counsel.
A number of Baum Hedlund’s legal victories have extended far beyond the courtroom. Our team of product liability attorneys have helped uncover harmful drug industry practices and deceptive marketing schemes orchestrated by Big Pharma, which have led to improved drug warning labels for consumers.